All News

RheumNow Podcast square

Does Fibromyalgia Need B12? (9.9.2022)

d Jack Cush, MD

Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.

Read Article
Study of 100 Korean systemic sclerosis pts, shows that while many had SSc finger involvement, fingerprints is SSc pts did not change significantly, but may be inadequate/ difficulr with finger deformity, acroosteolysis or digital ulcers https://t.co/JjTIiaLYZv https://t.co/kcFUobVnvi

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Goofy But True

d Jack Cush, MD

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.

Read Article
Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/szQmNPO0eu https://t.co/z4tdP4I1kc

Links:

Dr. John Cush RheumNow ( View Tweet)

Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/VKciXY0klN https://t.co/LdMu3RrlZK

Links:

Dr. John Cush RheumNow ( View Tweet)

Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/sGzWYLwcAZ https://t.co/7JiR0fe3GY

Links:

Dr. John Cush RheumNow ( View Tweet)
Rituximab Efficacy in Systemic Sclerosis The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase. https://t.co/8wWrt8GQ5v https://t.co/CIQKUyngN5

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Managing JDM with Calcinosis

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.

Read Article
PSS.scleroderma.arthritis.contractures

Rituximab Efficacy in Systemic Sclerosis

d Jack Cush, MD

The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.

Read Article
Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/qUOfMVSxGZ https://t.co/4icaRdC2EI

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Clinical Trial measures in systemic sclerosis: -RCTs focus on skin dz, ILD or Pulm HTN using mod. Rodnan skin (MRSS), 6-min walk -FVC is surrogate measure for SSc-ILD - Composites: CRISS, the EUSTAR-AI -Future: Skin mRNA biomarkersTHBS1 and COMP https://t.co/KPLiNTSSZA https://t.co/YgvWuMiU4i

Links:

Dr. John Cush RheumNow ( View Tweet)
IPF.JPG

Nintedinib’s Durable Efficacy in Systemic Sclerosis

d MedPage Today

Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.

Read Article
mitochondrial,DNA

Mitochondria as Master Regulators of Inflammation

d Jack Cush, MD

Mitochondrial constituents and metabolic products may give rise to immune activation; this is especially true for mitochondrial DNA, which can function as damage-associated molecular patterns (DAMPs) leading to inflammasome activation.

Read Article
Review of Clinical Trial measures in systemic sclerosis: -RCTs focus on skin dz, ILD or Pulm HTN using mod. Rodnan skin (MRSS), 6-min walk -FVC is surrogate measure for SSc-ILD - Composites: CRISS, the EUSTAR-AI -Future: Skin mRNA biomarkersTHBS1 and COMP https://t.co/2KD892VIUy https://t.co/9giddEl9I4

Links:

Dr. John Cush RheumNow ( View Tweet)
2021,year

ICYMI: 2021 Rheumatology Year in Review

d Jack Cush, MD

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Two Week Twitter (6.17.2022)

d Jack Cush, MD

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

Read Article
Baricitinib (JAK1/2 inhib) in 10 pts w/ systemic sclerosis showed improvement in modified Rodnan Skin Score ( −11.67 @wk 24; p=0.0008); 3/4 w/ digital ulcers healed at week 24. Similar findings seen in bleomycin induced animal model https://t.co/1G9CGjLK2N https://t.co/Gt35DcMyuz

Links:

Dr. John Cush RheumNow ( View Tweet)
Sousa et al. Anti-Ku disease. Cluster analysis (Ku alone, Ku with other abs) asking is is a distinct entity. In isolated anti-Ku+ maybe so, characterised by Raynauds (41%), arthritis (26%), sicca (26%), myositis (15%), ILD (15%) @RheumNow #EULAR2022 POS0861 https://t.co/IboWzMYFMB
Richard Conway RichardPAConway ( View Tweet)
Beyond capillaroscopy, US vascular imaging dorsal/ventral fingers can improve detection of vasculopathy of SSc in patients with Rayanaud's (RP) by Nam et al. The % vascular areas in patient's with RP was significantly lower in SSc vs normal volunteers #EULAR2022 @RheumNow POS0127

Dr. Antoni Chan synovialjoints ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.